Obtain variant constructs one month faster than using manual cloning
Case study: Generation of streamlined nanobody variant library for vaccine development with the BioXp® system
Compared to conventional antibodies, nanobodies — or heavy-chain antibodies — lack the usual light chain, and are therefore smaller, making them interesting candidates for biotherapeutic development.
The Depicker lab at Ghent University is studying how biotherapeutics focused on nanobodies could be used to prevent or treat infectious diseases and to improve design efforts for ongoing vaccine development.
In a recent project, the team set out to address the use of nanobodies as a novel delivery vehicle for more effective vaccine designs. They employed the BioXp® system to streamline construction of variants, replacing manual cloning methods that had been slow and labor-intensive.
Download the case study to see how the Depicker lab used the BioXp® system to build families of sequences with a design approach that used sequence homologies to gain efficiencies in synthesis, saving resources and associated costs, while consistently producing highly accurate constructs.
